Your browser is no longer supported. Please, upgrade your browser.
Settings
ALKS Alkermes plc daily Stock Chart
ALKS [NASD]
Alkermes plc
Index- P/E- EPS (ttm)-1.32 Insider Own0.80% Shs Outstand153.01M Perf Week-1.92%
Market Cap8.83B Forward P/E124.15 EPS next Y0.47 Insider Trans-17.80% Shs Float151.93M Perf Month0.12%
Income-199.90M PEG- EPS next Q-0.01 Inst Own- Short Float5.24% Perf Quarter2.05%
Sales780.70M P/S11.31 EPS this Y9.60% Inst Trans0.19% Short Ratio9.45 Perf Half Y3.13%
Book/sh7.97 P/B7.24 EPS next Y1275.00% ROA-11.50% Target Price63.50 Perf Year17.89%
Cash/sh3.11 P/C18.54 EPS next 5Y- ROE-16.40% 52W Range41.93 - 63.40 Perf YTD3.87%
Dividend- P/FCF- EPS past 5Y-6.80% ROI-13.60% 52W High-8.94% Beta2.25
Dividend %- Quick Ratio3.30 Sales past 5Y13.80% Gross Margin81.40% 52W Low37.68% ATR1.47
Employees1750 Current Ratio3.60 Sales Q/Q22.30% Oper. Margin-26.00% RSI (14)47.16 Volatility2.26% 2.57%
OptionableYes Debt/Eq0.23 EPS Q/Q12.10% Profit Margin-25.60% Rel Volume0.84 Prev Close57.53
ShortableYes LT Debt/Eq0.23 EarningsJul 27 BMO Payout- Avg Volume842.43K Price57.73
Recom2.40 SMA20-1.20% SMA50-1.25% SMA2002.55% Volume706,667 Change0.35%
Jun-13-17Downgrade Leerink Partners Outperform → Mkt Perform
Oct-21-16Upgrade JP Morgan Neutral → Overweight
Oct-21-16Reiterated Leerink Partners Outperform $57 → $70
Oct-21-16Reiterated Jefferies Buy $62 → $70
Oct-04-16Resumed Leerink Partners Outperform $57
Jan-21-16Reiterated Leerink Partners Outperform $84 → $58
Jan-21-16Downgrade Morgan Stanley Overweight → Underweight
Jan-21-16Downgrade JP Morgan Overweight → Neutral
Oct-07-15Reiterated Barclays Overweight $77 → $79
Sep-01-15Upgrade Morgan Stanley Underweight → Overweight
Jun-09-15Initiated Guggenheim Neutral
May-21-15Initiated Barclays Overweight $74
Jan-08-15Reiterated Mizuho Buy $72 → $81
Jul-31-14Reiterated Mizuho Buy $61 → $59
Apr-10-14Upgrade Mizuho Neutral → Buy $55 → $61
Apr-09-14Reiterated MKM Partners Sell $32 → $35
Feb-28-14Reiterated UBS Neutral $42 → $53
Feb-28-14Reiterated MKM Partners Sell $26 → $32
Feb-28-14Reiterated Mizuho Neutral $33 → $56
Dec-05-13Downgrade UBS Buy → Neutral $37 → $42
Jul-20-17 04:00PM  Alkermes to Host Conference Call to Discuss Second Quarter 2017 Financial Results Business Wire
Jul-19-17 09:12AM  Alkermes Plc breached its 50 day moving average in a Bearish Manner : ALKS-US : July 19, 2017 Capital Cube
Jul-14-17 12:43PM  ETFs with exposure to Alkermes Plc : July 14, 2017 Capital Cube
Jul-05-17 11:01AM  Attention Biotech Investors: Keep Your Date With July PDUFA Action-Days Benzinga
08:12AM  Biotech Stock Roundup: Cara Plunges on Study Data, Regulatory Updates & More Zacks
Jul-04-17 08:58AM  Alkermes Plc breached its 50 day moving average in a Bullish Manner : ALKS-US : July 4, 2017 Capital Cube
Jul-03-17 09:47AM  Alkermes Presents Phase III Data on Schizophrenia Candidate Zacks
Jun-29-17 04:00PM  Alkermes Announces Positive Preliminary Topline Results From Phase 3 Antipsychotic Efficacy Study of ALKS 3831 for Treatment of Schizophrenia Business Wire
Jun-20-17 03:38PM  Alkermes Plc Value Analysis (NASDAQ:ALKS) : June 20, 2017 Capital Cube
Jun-19-17 08:54AM  Alkermes Plc breached its 50 day moving average in a Bearish Manner : ALKS-US : June 19, 2017 Capital Cube
Jun-12-17 12:00PM  Alkermes Looks To Capitalize On Opioid Epidemic Through Aggressive Lobbying Benzinga
10:47AM  Alkermes Commences Phase III Study for Schizophrenia Drug Zacks
07:00AM  Alkermes Announces Initiation of Study 217 for ALKS 5461 for Treatment of Major Depressive Disorder Business Wire
Jun-08-17 04:00PM  Alkermes to Present at Goldman Sachs 38th Annual Global Healthcare Conference Business Wire
07:00AM  Alkermes Announces Initiation of Phase 3 Study of ALKS 3831 in Young Adult Patients Business Wire
Jun-07-17 10:54AM  Alkermes Gets FDA Nod for Two Month Dose of Aristada Zacks
10:01AM  Can Alkermes' Latest Approval Spark a Rally? Motley Fool
Jun-06-17 07:00AM  FDA Approves Two-Month ARISTADA® for Treatment of Schizophrenia Business Wire
Jun-05-17 07:47AM  Key FDA Events to Watch Out for in Jun 2017 Zacks
May-31-17 04:12AM  Alkermes (ALKS) Up 2.5% Since Earnings Report: Can It Continue? Zacks
May-30-17 04:20PM  Alkermes Corporate Presentation to Be Webcast at the Jefferies Healthcare Conference Business Wire
07:00AM  Alkermes Appoints Craig Hopkinson, M.D., as Chief Medical Officer, and Senior Vice President, Clinical Development and Medical Affairs Business Wire
May-26-17 08:28AM  Alkermes Plc breached its 50 day moving average in a Bearish Manner : ALKS-US : May 26, 2017 Capital Cube
May-15-17 03:16PM  Why These Drug Stocks May Surge Investopedia
01:23PM  Big Week Ahead for Alkermes Investopedia
08:20AM  Alkermes Plc breached its 50 day moving average in a Bullish Manner : ALKS-US : May 15, 2017 Capital Cube
May-11-17 04:00PM  Alkermes to Present Data on ALKS 5461 at Upcoming Society of Biological Psychiatry Annual Meeting Business Wire
May-04-17 09:08AM  3 Biotech Stocks Projected to Grow Their EPS by at Least 415% in 2018 Motley Fool
May-02-17 11:05AM  [$$] Three Top Picks in Smaller Pharma Barrons.com
08:15AM  Blog Coverage Alkermes Announces Completion of Patient Enrolment in ALKS 3831 Study for the Treatment of Schizophrenia Accesswire
May-01-17 04:11PM  Biotechs Cruise On 6-Day Upswing Despite Price Target Cuts For This Duo Investor's Business Daily
03:34PM  ETFs with exposure to Alkermes Plc : May 1, 2017 Capital Cube
09:27AM  Alkermes' Revenue Jumps 22% Motley Fool
08:11AM  Alkermes Plc breached its 50 day moving average in a Bullish Manner : ALKS-US : May 1, 2017 Capital Cube
07:00AM  Alkermes Announces Completion of Patient Enrollment in Pivotal Antipsychotic Efficacy Study of ALKS 3831 for Schizophrenia Business Wire
Apr-28-17 07:55PM  Edited Transcript of ALKS earnings conference call or presentation 27-Apr-17 12:30pm GMT Thomson Reuters StreetEvents
11:11AM  Alkermes Plc :ALKS-US: Earnings Analysis: Q1, 2017 By the Numbers : April 28, 2017 Capital Cube
08:51AM  Alkermes (ALKS) Q1 Loss Wider than Expected, Sales Miss Zacks
Apr-27-17 04:07PM  Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports TheStreet.com
08:56AM  Alkermes reports 1Q loss Associated Press
08:51AM  Biotech Earnings Roundup: Exact Sciences Flying Higher Investopedia
07:00AM  Alkermes plc Reports First Quarter 2017 Financial Results Business Wire
Apr-26-17 04:00PM  Alkermes Corporate Presentation to be Webcast at the Deutsche Bank 42nd Annual Health Care Conference Business Wire
Apr-20-17 04:00PM  Alkermes to Host Conference Call to Discuss First Quarter 2017 Financial Results Business Wire
Apr-13-17 12:45PM  Alkermes Plc Value Analysis (NASDAQ:ALKS) : April 13, 2017 Capital Cube
Apr-12-17 08:18AM  Alkermes Plc breached its 50 day moving average in a Bearish Manner : ALKS-US : April 12, 2017 Capital Cube
Apr-07-17 08:47AM  5 Drug Stocks for Your Portfolio this World Health Day Zacks
Apr-04-17 01:20PM  Drug Addiction Treatment Should Start in Emergency Room GuruFocus.com
01:20PM  Drug Addiction Treatment Should Start in Emergency Room
Apr-03-17 04:43PM  Acorda, Forward, Biogen Fall On Multiple Sclerosis Drug Fight Investor's Business Daily
04:43PM  Acorda, Forward, Biogen Fall On Multiple Sclerosis Drug Fight
04:23PM  3 Top Biotech Stocks to Buy in April Motley Fool
04:23PM  3 Top Biotech Stocks to Buy in April at Motley Fool
Mar-31-17 04:46PM  ALKERMES PLC. Files SEC form 8-K, Other Events
04:36PM  Vivitrol Offers Hope Against Opioid Addiction Investopedia
04:36PM  Vivitrol Offers Hope Against Opioid Addiction at Investopedia
12:15PM  Forward Pharma Falls On Biogen Patent Victory Over MS Drug Ingredient
Mar-27-17 07:00AM  Alkermes to Present Preclinical Data on ALKS 4230 at the American Association for Cancer Research Annual Meeting Business Wire
Mar-20-17 07:00AM  Alkermes to Present Data on Two-Month Dosing Option Of ARISTADA® at 16th International Congress on Schizophrenia Research Business Wire
Mar-18-17 12:26PM  Companies Aiming for the Billion-Dollar Opioid Addiction Market
Mar-17-17 05:58PM  Alkermes Starts Phase III Study to Treat Multiple Sclerosis Zacks
05:58PM  Alkermes Starts Phase III Study to Treat Multiple Sclerosis
Mar-16-17 07:00AM  Alkermes Initiates Phase 3 Gastrointestinal Tolerability Study of ALKS 8700 for Treatment of Multiple Sclerosis Business Wire
Mar-14-17 08:50AM  Alkermes Plc breached its 50 day moving average in a Bearish Manner : ALKS-US : March 14, 2017 Capital Cube
08:50AM  Alkermes Plc breached its 50 day moving average in a Bearish Manner : ALKS-US : March 14, 2017
Mar-10-17 07:16AM  ALKERMES PLC. Files SEC form 8-K, Other Events
Mar-08-17 12:40PM  The 'Gnarly 9' Biotechs Will Test the FDA's Mettle
12:40PM  [video]The 'Gnarly 9' Biotechs Will Test the FDA's Mettle
10:26AM  The 'Gnarly 9' Biotechs Will Test the FDA's Mettle
Mar-07-17 04:00PM  Alkermes Corporate Presentation to be Webcast at the Barclays Global Healthcare Conference Business Wire
Mar-06-17 09:21AM  4 Things Alkermes Wants Investors to Know at Motley Fool
Mar-02-17 01:06PM  Heres What Mott Capital Management Thinks About Netflix, Alkermes, Vodafone & More at Insider Monkey
Feb-28-17 04:00PM  Alkermes Corporate Presentation to be Webcast at the Cowen and Company 37th Annual Health Care Conference Business Wire
Feb-22-17 03:52PM  Drug Addiction Treatment Stocks to Watch
01:04PM  ALKERMES PLC. Financials
Feb-17-17 11:36AM  Alkermes Plc :ALKS-US: Earnings Analysis: 2016 By the Numbers : February 17, 2017
07:05AM  ALKERMES PLC. Files SEC form 10-K, Annual Report
Feb-16-17 05:38PM  Stress boom to boost drug sales?
04:10PM  Alkermes (ALKS) Q4 Loss Narrower than Expectations, Sales Beat
10:01AM  Alkermes Plc :ALKS-US: Earnings Analysis: Q4, 2016 By the Numbers : February 16, 2017
09:04AM  Alkermes' Revenue Soars, Projects an Exciting Year Ahead at Motley Fool
Feb-15-17 05:17PM  Edited Transcript of ALKS earnings conference call or presentation 15-Feb-17 1:30pm GMT
10:45AM  A solution to improve your patience as a trader
08:30AM  Alkermes Plc Earnings Call scheduled for 8:30 am ET today
07:16AM  Alkermes reports 4Q loss
07:13AM  ALKERMES PLC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
07:07AM  Q4 2016 Alkermes Plc Earnings Release - Before Market Open
07:00AM  Alkermes plc Reports Financial Results for the Year Ended Dec. 31, 2016 and Provides Financial Expectations for 2017 Business Wire
Feb-13-17 05:17PM  Why Sage Therapeutics Jumped Today at Motley Fool
Feb-08-17 04:00PM  Alkermes to Host Conference Call to Discuss Fourth Quarter and Year-End 2016 Financial Results Business Wire
Feb-06-17 12:47PM  Is Alkermes Poised for a Comeback in 2017? at Motley Fool
Feb-05-17 06:21PM  Naltrexone Showing More Potential in Drug Addiction Treatment Market
Feb-03-17 01:25PM  Alkermes to expand manufacturing capacity, add new jobs at bizjournals.com
Jan-25-17 01:44PM  Meet Morningstar's 2016 top domestic fund manager
Jan-22-17 01:13PM  BioCorRx Receives New Funding for Opioid Drug
Jan-13-17 03:33PM  Mott Capital Says Netflix (NFLX) At Forefront of Paradigm Shift, Talks Disney, Hain, NXPI Deal, More at Insider Monkey
Jan-11-17 08:15AM  Blog Coverage Valeant Sells-Off Its Skin Care Brands to L'Oreal Accesswire -6.65%
Jan-05-17 02:44PM  Top Biotech Picks: "The Strong Will Survive And Thrive" at Barrons.com
10:35AM  Alkermes Plc Value Analysis (NASDAQ:ALKS) : January 5, 2017
Jan-04-17 08:07AM  Alkermes Plc breached its 50 day moving average in a Bullish Manner : ALKS-US : January 4, 2017 +6.77%
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products that are designed to address unmet medical needs of patients in various therapeutic areas worldwide. The company's marketed products include ARISTADA (aripiprazole lauroxil) for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis who have walking disability; and BYDUREON (exenatide extended-release for injectable suspension) for the treatment of type 2 diabetes. It is also developing ALKS 5461 that is in Phase III clinical trials for the treatment of depressive disorder; ALKS 3831, which is in Phase III clinical trials to treat schizophrenia; ALKS 8700, a monomethyl fumarate molecule, which is in Phase III clinical trials to treat multiple sclerosis; ALKS 6428, which is in Phase III clinical trials to help physicians transition patients from physical dependence on opioids; and Aripiprazole lauroxil, an injectable atypical antipsychotic, which has completed a Phase I clinical trials for the treatment of schizophrenia, as well as ALKS 4230, a cell activator that is in Phase I clinical trials for cancer immunotherapy. The company serves pharmaceutical wholesalers, and specialty pharmacies and distributors. It has collaboration agreements with Ortho-McNeil-Janssen Pharmaceuticals, Inc. and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MITCHELL PAUL JDirectorJul 03Option Exercise11.441,50017,1609,500Jul 06 05:36 PM
MITCHELL PAUL JDirectorJul 03Sale58.111,50087,1658,000Jul 06 05:36 PM
Cooke ShanePresident, Alkermes plcJun 08Option Exercise16.5510,000165,50084,708Jun 08 05:33 PM
Stejbach MarkSVP/Chief Comm Off, Alks IncJun 08Option Exercise17.3010,000173,00054,013Jun 08 05:41 PM
Stejbach MarkSVP/Chief Comm Off, Alks IncJun 08Sale60.3410,000603,35244,013Jun 08 05:41 PM
Cooke ShanePresident, Alkermes plcJun 08Sale60.3310,000603,33374,708Jun 08 05:33 PM
MITCHELL PAUL JDirectorJun 01Option Exercise11.441,50017,1609,500Jun 01 05:21 PM
MITCHELL PAUL JDirectorJun 01Sale57.491,50086,2358,000Jun 01 05:21 PM
BIBERSTEIN KATHRYN LEVP/CAO/CCO Alks Inc; Sec ALKSMay 28Option Exercise0.003,750058,654May 30 05:16 PM
Brown Iain MichaelSVP Finance & CAO, Alks Inc.May 28Option Exercise0.001,750028,163May 30 05:20 PM
Cooke ShanePresident, Alkermes plcMay 28Option Exercise0.005,750077,698May 30 05:23 PM
Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc.May 28Option Exercise0.003,750058,821May 30 05:30 PM
FRATES JAMES MSVP, Alks Inc; CFO ALKSMay 28Option Exercise0.002,5000130,654May 30 05:39 PM
Gaffin David JosephSVP, CLO, Alkermes, Inc.May 28Option Exercise0.001,250031,563May 30 05:42 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.May 28Option Exercise0.002,5000164,870May 30 05:46 PM
POPS RICHARD FDirector and CEO, Alkermes plcMay 28Option Exercise0.0013,7500644,156May 30 05:49 PM
Stejbach MarkSVP/Chief Comm Off, Alks IncMay 28Option Exercise0.002,500044,013May 30 05:51 PM
POPS RICHARD FDirector and CEO, Alkermes plcMay 24Option Exercise15.9525,000398,750655,406May 25 05:34 PM
POPS RICHARD FDirector and CEO, Alkermes plcMay 24Sale57.4225,0001,435,535630,406May 25 05:34 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.May 18Option Exercise15.9510,000159,500172,370May 19 05:58 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.May 18Sale57.2310,000572,254162,370May 19 05:58 PM
POPS RICHARD FDirector and CEO, Alkermes plcMay 17Option Exercise15.9550,000797,500680,406May 19 05:28 PM
Gaffin David JosephSVP, CLO, Alkermes, Inc.May 17Option Exercise15.952,25035,88830,313May 19 05:19 PM
POPS RICHARD FDirector and CEO, Alkermes plcMay 17Sale58.1950,0002,909,439630,406May 19 05:28 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.May 11Option Exercise15.9510,000159,500172,370May 11 05:06 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.May 11Sale57.0110,000570,082162,370May 11 05:06 PM
POPS RICHARD FDirector and CEO, Alkermes plcMay 10Option Exercise15.9525,000398,750655,406May 11 05:03 PM
POPS RICHARD FDirector and CEO, Alkermes plcMay 10Sale57.2925,0001,432,244630,406May 11 05:03 PM
Cooke ShanePresident, Alkermes plcMay 04Option Exercise16.556,500107,57578,448May 04 05:26 PM
Cooke ShanePresident, Alkermes plcMay 04Sale60.056,500390,32871,948May 04 05:26 PM
MITCHELL PAUL JDirectorMay 01Option Exercise11.441,50017,1609,500May 03 05:19 PM
Cooke ShanePresident, Alkermes plcMay 01Option Exercise16.553,50057,92575,448May 03 05:30 PM
MITCHELL PAUL JDirectorMay 01Sale58.741,50088,1108,000May 03 05:19 PM
Cooke ShanePresident, Alkermes plcMay 01Sale60.053,500210,16571,948May 03 05:30 PM
Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc.Apr 17Option Exercise16.5510,000165,50065,071Apr 18 05:13 PM
Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc.Apr 17Sale56.6010,000565,98655,071Apr 18 05:13 PM
MITCHELL PAUL JDirectorApr 03Option Exercise11.441,50017,1609,500Apr 04 05:12 PM
BIBERSTEIN KATHRYN LEVP/CAO/CCO Alks Inc; Sec ALKSApr 03Option Exercise15.9515,000239,25069,904Apr 04 05:28 PM
MITCHELL PAUL JDirectorApr 03Sale58.311,50087,4658,000Apr 04 05:12 PM
BIBERSTEIN KATHRYN LEVP/CAO/CCO Alks Inc; Sec ALKSApr 03Sale57.6815,000865,23454,904Apr 04 05:28 PM
Cooke ShanePresident, Alkermes plcMar 29Option Exercise16.362,07033,86974,018Mar 29 05:20 PM
Cooke ShanePresident, Alkermes plcMar 29Sale60.002,070124,20071,948Mar 29 05:20 PM
Cooke ShanePresident, Alkermes plcMar 23Option Exercise15.586,03093,94777,978Mar 27 05:32 PM
Cooke ShanePresident, Alkermes plcMar 23Sale60.016,030361,85671,948Mar 27 05:32 PM
Cooke ShanePresident, Alkermes plcMar 21Option Exercise15.701,60025,11573,548Mar 22 06:45 PM
Cooke ShanePresident, Alkermes plcMar 21Sale60.101,60096,16271,948Mar 22 06:45 PM
Cooke ShanePresident, Alkermes plcMar 20Option Exercise15.903004,77072,248Mar 22 06:45 PM
Cooke ShanePresident, Alkermes plcMar 20Sale60.0030018,00071,948Mar 22 06:45 PM
Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc.Mar 15Option Exercise16.5510,000165,50066,071Mar 16 06:17 PM
Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc.Mar 15Sale56.7411,000624,10755,071Mar 16 06:17 PM
BIBERSTEIN KATHRYN LEVP/CAO/CCO Alks Inc; Sec ALKSMar 10Option Exercise12.298,137100,00454,904Mar 10 05:13 PM
FRATES JAMES MSVP, Alks Inc; CFO ALKSMar 07Option Exercise16.5525,000413,750144,053Mar 07 05:29 PM
FRATES JAMES MSVP, Alks Inc; CFO ALKSMar 07Sale59.0825,0001,477,068119,053Mar 07 05:29 PM
Stejbach MarkSVP/Chief Comm Off, Alks IncMar 03Option Exercise0.002,812041,513Mar 06 05:50 PM
POPS RICHARD FDirector and CEO, Alkermes plcMar 03Option Exercise0.0013,0000636,523Mar 06 05:47 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Mar 03Option Exercise0.002,8120163,283Mar 06 05:42 PM
Gaffin David JosephSVP, CLO, Alkermes, Inc.Mar 03Option Exercise0.001,250028,469Mar 06 05:40 PM
FRATES JAMES MSVP, Alks Inc; CFO ALKSMar 03Option Exercise0.002,8120119,966Mar 06 05:37 PM
Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc.Mar 03Option Exercise0.003,750057,836Mar 06 05:35 PM
Cooke ShanePresident, Alkermes plcMar 03Option Exercise0.005,250074,678Mar 06 05:34 PM
Brown Iain MichaelSVP Finance & CAO, Alks Inc.Mar 03Option Exercise0.001,250026,819Mar 06 05:32 PM
BIBERSTEIN KATHRYN LEVP/CAO/CCO Alks Inc; Sec ALKSMar 03Option Exercise0.003,500048,414Mar 06 05:31 PM
Cooke ShanePresident, Alkermes plcMar 02Option Exercise14.6020,000292,00089,428Mar 02 05:57 PM
BREYER ROBERT ADirectorMar 02Sale60.004,000240,0007,156Mar 02 05:53 PM
Cooke ShanePresident, Alkermes plcMar 02Sale60.0020,0001,200,00069,428Mar 02 05:57 PM
MITCHELL PAUL JDirectorMar 01Option Exercise11.441,50017,1609,500Mar 02 05:21 PM
BIBERSTEIN KATHRYN LEVP/CAO/CCO Alks Inc; Sec ALKSMar 01Option Exercise0.005,750046,970Mar 02 05:47 PM
Brown Iain MichaelSVP Finance & CAO, Alks Inc.Mar 01Option Exercise0.002,250026,300Mar 02 05:55 PM
Cooke ShanePresident, Alkermes plcMar 01Option Exercise0.007,000073,068Mar 02 05:57 PM
Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc.Mar 01Option Exercise0.005,750056,792Mar 02 06:00 PM
FRATES JAMES MSVP, Alks Inc; CFO ALKSMar 01Option Exercise0.004,5000118,615Mar 02 06:04 PM
Gaffin David JosephSVP, CLO, Alkermes, Inc.Mar 01Option Exercise0.002,250027,950Mar 02 06:07 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Mar 01Option Exercise0.004,5000161,932Mar 02 06:15 PM
POPS RICHARD FDirector and CEO, Alkermes plcMar 01Option Exercise0.0017,5000631,757Mar 02 06:17 PM
Stejbach MarkSVP/Chief Comm Off, Alks IncMar 01Option Exercise0.005,250041,138Mar 02 06:19 PM
MITCHELL PAUL JDirectorMar 01Sale57.061,50085,5908,000Mar 02 05:21 PM
BIBERSTEIN KATHRYN LEVP/CAO/CCO Alks Inc; Sec ALKSFeb 26Option Exercise0.003,750042,437Feb 27 05:32 PM
Brown Iain MichaelSVP Finance & CAO, Alks Inc.Feb 26Option Exercise0.001,100024,407Feb 27 05:34 PM
Cooke ShanePresident, Alkermes plcFeb 26Option Exercise0.004,425068,369Feb 27 05:35 PM
Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc.Feb 26Option Exercise0.003,750052,807Feb 27 05:41 PM
Gaffin David JosephSVP, CLO, Alkermes, Inc.Feb 26Option Exercise0.001,100026,057Feb 27 05:43 PM
FRATES JAMES MSVP, Alks Inc; CFO ALKSFeb 26Option Exercise0.002,6250114,967Feb 27 05:46 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Feb 26Option Exercise0.002,6250158,284Feb 27 05:48 PM
POPS RICHARD FDirector and CEO, Alkermes plcFeb 26Option Exercise0.0010,0000618,962Feb 27 05:50 PM
Stejbach MarkSVP/Chief Comm Off, Alks IncFeb 26Option Exercise0.002,625036,740Feb 27 05:52 PM
Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc.Feb 16Option Exercise16.5510,000165,50059,657Feb 16 05:56 PM
Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc.Feb 16Sale56.5310,000565,27149,657Feb 16 05:56 PM
Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc.Feb 15Sale58.171,00058,17049,657Feb 16 05:56 PM
MITCHELL PAUL JDirectorFeb 01Option Exercise11.441,50017,1609,500Feb 02 06:22 PM
MITCHELL PAUL JDirectorFeb 01Sale54.451,50081,6758,000Feb 02 06:22 PM
Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc.Jan 17Option Exercise16.5510,000165,50062,640Jan 18 05:06 PM
Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc.Jan 17Sale54.3211,983650,94550,657Jan 18 05:06 PM
Stejbach MarkSVP/Chief Comm Off, Alks IncJan 09Option Exercise17.305479,46334,662Jan 10 05:08 PM
Cooke ShanePresident, Alkermes plcJan 09Option Exercise14.605508,03064,494Jan 10 05:10 PM
Stejbach MarkSVP/Chief Comm Off, Alks IncJan 09Sale60.2754732,96834,115Jan 10 05:08 PM
Cooke ShanePresident, Alkermes plcJan 09Sale60.2755033,14963,944Jan 10 05:10 PM
Stejbach MarkSVP/Chief Comm Off, Alks IncJan 06Option Exercise17.306,653115,09740,768Jan 06 07:32 PM
Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc.Jan 06Option Exercise18.112,10038,02154,740Jan 06 06:28 PM
Cooke ShanePresident, Alkermes plcJan 06Option Exercise14.606,60796,46270,551Jan 06 06:36 PM
Stejbach MarkSVP/Chief Comm Off, Alks IncJan 06Sale60.076,653399,64334,115Jan 06 07:32 PM